Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 9;63(12):e01733-19.
doi: 10.1128/AAC.01733-19. Epub 2019 Oct 7.

Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae

Cornelius J Clancy  1 , M Hong Nguyen  2
Affiliations

Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae

Cornelius J Clancy et al. Antimicrob Agents Chemother. .

Abstract

New antibiotics with activity against carbapenem-resistant Enterobacteriaceae (CRE) improve outcomes of CRE-infected patients. However, companies developing these drugs have faced financial difficulties. Sales of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin in the United States (US) totaled $101 million from February 2018-January 2019. We estimate the current annual US market for new anti-CRE antibiotics is $289 million (range: $169-$439 million). Without new antibiotic development models and/or reimbursement reform, the majority of anti-CRE drugs will be commercially inviable.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Monthly sales of ceftazidime-avibactam, meropenem-vaborbactam, and plazomicin in the United States. Sales data are presented as 3-month moving averages in U.S. dollars, beginning with the introduction of ceftazidime-avibactam to the market. The dip and subsequent rebound in sales of ceftazidime-avibactam in 2016 and 2017 corresponded to a nationwide supply shortage of the drug and its resolution.
See this image and copyright information in PMC

References

    1. Temkin E, Fallach N, Almagor J, Gladstone BP, Tacconelli E, Carmeli Y, Consortium D-A. 2018. Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study. Lancet Glob Health 6:e969–e979. doi:10.1016/S2214-109X(18)30278-X. - DOI - PubMed
    1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group. 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18:318–327. doi:10.1016/S1473-3099(17)30753-3. - DOI - PubMed
    1. Clancy CJ, Potoski BA, Buehrle D, Nguyen MH. 2019. Estimating the treatment of carbapenem-resistant Enterobacteriaceae infections in the United States using antibiotic prescription data. Open Forum Infect Dis 6:ofz344. doi:10.1093/ofid/ofz344. - DOI - PMC - PubMed
    1. McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, Jubb AM, Serio AW, Krause KM, Daikos GL, Group CS. 2019. Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae. N Engl J Med 380:791–793. doi:10.1056/NEJMc1807634. - DOI - PubMed
    1. Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ. 2017. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 61:e00883-17. doi:10.1128/AAC.00883-17. - DOI - PMC - PubMed

LinkOut - more resources